Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.77 |
| ▸ | PPARA | Q07869 | 16/20 | 0.77 |
| ▸ | PPARD | Q03181 | 9/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689835 | 0.89 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL2811302 | 0.87 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL4692405 | 0.87 | PPARG (0.80) | PPARGPPARAPPARD | |
| SCHEMBL5100836 | 0.86 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL2808248 | 0.83 | PPARA (1.00) | PPARGPPARAPPARD | |
| SCHEMBL4689579 | 0.79 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL18644965 | 0.79 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL4689934 | 0.78 | PPARG (0.85) | PPARGPPARAPPARD | |
| SCHEMBL4692383 | 0.78 | PPARG (0.82) | PPARGPPARAPPARD | |
| SCHEMBL4692677 | 0.78 | PPARG (0.67) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | claimed |
| JP-2007511485-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | claimed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.